Neogen Swings to Profit on $76M Business Sale Gain, Revenue Dips

TL;DR

**NEOG's one-time business sale gain is papering over soft revenue, but the debt reduction is a smart move for long-term stability.**

AI Summary

NEOGEN CORP reported a significant turnaround for the three months ended August 31, 2025, achieving a net income of $36.338 million, a substantial improvement from the net loss of $12.609 million in the prior-year period. This positive shift was primarily driven by a $76.390 million gain on the sale of its Cleaners and Disinfectants (C&D) business to Kersia Group, completed on July 17, 2025. Total revenues, however, saw a slight decrease of 3.59%, falling to $209.189 million from $216.964 million, with product revenues declining by $8.380 million. Operating expenses increased by 8.17% to $111.061 million, largely due to a rise in general and administrative expenses from $51.671 million to $60.888 million. Despite the revenue dip and increased operating costs, the divestiture significantly bolstered the company's financial position, leading to a basic net income per share of $0.17 compared to a loss of $0.06 per share previously. Cash and cash equivalents increased to $138.883 million from $129.004 million at May 31, 2025, partly due to $121.724 million in proceeds from the C&D business sale. The company also reduced non-current debt by $82.280 million to $792.530 million.

Why It Matters

This 10-Q reveals NEOGEN's strategic pivot, shedding a non-core asset to improve profitability and reduce debt. The $76.390 million gain on the C&D business sale is a one-time boost, masking a slight revenue decline in core operations, which could concern investors looking for organic growth. For employees, the divestiture may signal a sharper focus on food and animal safety segments, potentially impacting roles within the divested C&D unit. Customers of the C&D business will now interact with Kersia Group, while Neogen's remaining customers should see continued focus. In a competitive market, this move allows Neogen to streamline its portfolio and potentially invest more in its key diagnostic and genomics offerings, impacting rivals like IDEXX Laboratories and Thermo Fisher Scientific.

Risk Assessment

Risk Level: medium — The company's operating loss of $16.091 million for the quarter, compared to an operating income of $2.257 million in the prior year, indicates underlying operational challenges. While the $76.390 million gain on sale of business significantly boosted net income, this is a non-recurring event, suggesting that core profitability needs improvement to sustain positive results. The 3.59% decline in total revenues also points to potential headwinds in its ongoing business segments.

Analyst Insight

Investors should look beyond the one-time gain from the C&D business sale and scrutinize NEOGEN's core operating performance. Monitor future revenue trends in the Food Safety and Animal Safety segments and assess management's strategy for organic growth and profitability improvement. The debt reduction is a positive, but sustained operational profitability is key for long-term value.

Financial Highlights

debt To Equity

0.37

revenue

$209,189,000

operating Margin

45.40%

total Assets

$3,378,156,000

total Debt

$792,530,000

net Income

$36,338,000

eps

$0.17

gross Margin

45.40%

cash Position

$138,883,000

revenue Growth

-3.59%

Revenue Breakdown

Key Numbers

• $36.338M — Net Income (Swung from a $12.609M net loss in Q1 2024, primarily due to divestiture gain.)
• $76.390M — Gain on Sale of Business (Key driver of net income, from the sale of the C&D business to Kersia Group.)
• $209.189M — Total Revenues (Decreased by 3.59% from $216.964M in Q1 2024.)
• $16.091M — Operating Loss (Compared to an operating income of $2.257M in Q1 2024, indicating core operational challenges.)
• $138.883M — Cash and Cash Equivalents (Increased from $129.004M at May 31, 2025, partly due to divestiture proceeds.)
• $792.530M — Non-Current Debt (Reduced by $82.280M from $874.810M at May 31, 2025.)
• $0.17 — Basic Net Income Per Share (Improved from a basic net loss per share of $0.06 in Q1 2024.)
• 217,298,626 — Common Stock Outstanding (As of August 31, 2025.)

Key Players & Entities

• NEOGEN CORP (company) — registrant
• Kersia Group (company) — acquirer of C&D business
• $36.338 million (dollar_amount) — net income for Q1 2025
• $12.609 million (dollar_amount) — net loss for Q1 2024
• $76.390 million (dollar_amount) — gain on sale of business
• $209.189 million (dollar_amount) — total revenues for Q1 2025
• $216.964 million (dollar_amount) — total revenues for Q1 2024
• $111.061 million (dollar_amount) — total operating expenses for Q1 2025
• $16.091 million (dollar_amount) — operating loss for Q1 2025
• $792.530 million (dollar_amount) — non-current debt as of August 31, 2025

FAQ

Risk Factors

• Integration of Divested Business [medium — operational]: The company completed the sale of its Cleaners and Disinfectants (C&D) business on July 17, 2025. While this generated a significant gain, the divestiture of a business segment could lead to operational disruptions, loss of key personnel, and challenges in integrating remaining operations or managing the transition. The company needs to ensure continued focus on its core businesses post-divestiture.
• Competition in Animal Health and Food Safety [medium — market]: Neogen operates in competitive markets for animal health and food safety diagnostics. The company faces competition from numerous domestic and international companies, some of which may have greater financial resources or a broader product portfolio. Sustained innovation and effective market penetration are crucial to maintaining market share and profitability.
• Debt Management [medium — financial]: As of August 31, 2025, Neogen reported $792.530 million in non-current debt. While this was reduced by $82.280 million from May 31, 2025, managing this debt level is critical. High debt levels can increase financial risk, impact borrowing capacity, and affect interest expense, especially in a rising interest rate environment.
• Product Development and Regulatory Approval [low — regulatory]: The development and introduction of new products, particularly in regulated markets like food safety and animal health, require significant investment and are subject to stringent regulatory approvals. Delays or failures in obtaining necessary approvals can impact revenue streams and competitive positioning.

Industry Context

Neogen operates in the animal health and food safety sectors, which are characterized by increasing demand for diagnostics, testing, and biosecurity solutions driven by global food production, regulatory requirements, and consumer safety concerns. The industry is competitive, with players focusing on innovation, product breadth, and global reach. Trends include advancements in genomic testing, rapid diagnostics, and integrated solutions for farm-to-fork safety.

Regulatory Implications

Neogen's products are subject to various regulatory approvals and standards in different jurisdictions, particularly for food safety and animal health applications. Compliance with these regulations is critical for market access and maintaining product integrity. Changes in regulatory landscapes or enforcement can impact product development timelines and marketability.

What Investors Should Do

1. Monitor core business performance post-divestiture.
2. Evaluate the impact of increased operating expenses.
3. Assess the strategic use of divestiture proceeds.
4. Analyze the trend in product revenues.

Key Dates

• 2025-07-17: Sale of Cleaners and Disinfectants (C&D) business to Kersia Group completed — Generated a $76.390 million gain, significantly boosting net income for the quarter and improving the company's cash position.
• 2025-08-31: End of the three-month period for the reported 10-Q — Represents the reporting date for the condensed consolidated financial statements, showing a turnaround in net income.
• 2024-08-31: End of the prior-year comparable three-month period — Used as a benchmark to show a significant improvement in net income from a loss of $12.609 million to a gain of $36.338 million.
• 2025-05-31: End of the prior fiscal year's reporting period — Used as a comparison point for balance sheet items, showing an increase in cash and a reduction in non-current debt.

Glossary

Accumulated deficit

The cumulative net losses of a company since its inception, minus any cumulative net income. (Neogen's accumulated deficit decreased from $(536,424,000) to $(500,086,000) due to the significant net income in the current quarter, indicating a reduction in overall historical losses.)

Assets held for sale

Assets that a company intends to sell within one year and are actively marketed. They are typically reported at the lower of their carrying amount or fair value less costs to sell. (This line item was $50,402,000 as of May 31, 2025, and is now zero, reflecting the completion of the sale of the C&D business.)

Goodwill

An intangible asset that arises when a company acquires another company for a price greater than the fair value of its identifiable net assets. (Neogen has substantial goodwill ($1,065,889,000 as of August 31, 2025), primarily from past acquisitions, which is subject to impairment testing.)

Amortizable intangible assets, net

Intangible assets, such as patents or customer lists, that have a finite useful life and are expensed over that life through amortization. (Neogen has significant amortizable intangible assets ($1,389,141,000 as of August 31, 2025), which are being systematically reduced over time.)

Right of use assets

Assets recognized under accounting standards for leases, representing the right to use an underlying asset for the lease term. (These represent Neogen's leased assets, totaling $16,994,000 as of August 31, 2025.)

Year-Over-Year Comparison

Compared to the three months ended August 31, 2024, Neogen Corp. has demonstrated a significant financial turnaround, swinging from a net loss of $12.609 million to a net income of $36.338 million, largely due to a $76.390 million gain on the sale of its C&D business. Total revenues saw a slight decrease of 3.59% to $209.189 million, with product revenues declining. Operating expenses increased by 8.17% to $111.061 million, driven by higher general and administrative costs. Despite these operational cost increases and revenue dip, the divestiture significantly improved the company's financial position, evidenced by increased cash and reduced non-current debt.

Key Financial Figures

• $0.16 — e on which registered Common Stock, $0.16 par value per share NEOG NASDAQ Glo

Filing Documents

• neog-20250831.htm (10-Q) — 1666KB
• neog-ex10_1.htm (EX-10.1) — 50KB
• neog-ex10_2.htm (EX-10.2) — 28KB
• neog-ex10_3.htm (EX-10.3) — 34KB
• neog-ex10_4.htm (EX-10.4) — 52KB
• neog-ex10_5.htm (EX-10.5) — 35KB
• neog-ex31_1.htm (EX-31.1) — 15KB
• neog-ex31_2.htm (EX-31.2) — 15KB
• neog-ex32.htm (EX-32) — 13KB
• img192722933_0.jpg (GRAPHIC) — 54KB
• img194660645_0.jpg (GRAPHIC) — 632KB
• img195493496_0.jpg (GRAPHIC) — 54KB
• 0001193125-25-235720.txt ( ) — 9507KB
• neog-20250831.xsd (EX-101.SCH) — 1293KB
• neog-20250831_htm.xml (XML) — 1272KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1. Interim Condensed Consolidated Financial Statements (unaudited) 2 Condensed Consolidated Balance Sheets – August 31, 2025 and May 31, 2025 2 Condensed Consolidated Statements of Operations – three months ended August 31, 2025 and August 31, 2024 3 Condensed Consolidated Statements of Comprehensive (Loss) Income – three months ended August 31, 2025 and August 31, 2024 4 Condensed Consolidated Statements of Equity – three months ended August 31, 2025 and August 31, 2024 5 Condensed Consolidated Statements of Cash Flows – Three months ended August 31, 2025 and August 31, 2024 6 Notes to Interim Condensed Consolidated Financial Statements – August 31, 2025 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 22 Item 4.

Controls and Procedures

Controls and Procedures 23

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 24 Item 1A.

Risk Factors

Risk Factors 24 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 24 Item 5. Other Information 24 Item 6. Exhibits 25

SIGNATURES

SIGNATURES 26 CEO Certification CFO Certification Section 906 Certification 1

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Interim Condensed Consolidated Financial Statements

Item 1. Interim Condensed Consolidated Financial Statements Neogen Corporation Condensed Consolidated Balance Sheets (in thousands, except shares) August 31, 2025 May 31, 2025 Assets (unaudited) Current Assets Cash and cash equivalents $ 138,883 $ 129,004 Accounts receivable, net of allowance of $ 5,403 and $ 5,397 138,459 153,384 Inventories Raw materials 66,831 65,692 Work-in-process 11,636 11,233 Finished goods 131,812 130,417 Total Inventories 210,279 207,342 Less inventory reserve ( 16,865 ) ( 16,483 ) Inventories, net 193,414 190,859 Assets held for sale — 50,402 Prepaid expenses and other current assets 53,304 53,288 Total Current Assets 524,060 576,937 Net Property and Equipment 345,893 339,131 Other Assets Right of use assets 16,994 17,152 Goodwill 1,065,889 1,064,902 Amortizable intangible assets, net 1,389,141 1,410,485 Other non-current assets 36,179 35,229 Total Other Assets 2,508,203 2,527,768 Total Assets $ 3,378,156 $ 3,443,836 Liabilities and Stockholders' Equity Current Liabilities Current portion of debt $ — $ 19,301 Accounts payable 76,596 79,605 Accrued compensation 20,273 14,134 Income tax payable (note 8) 9,449 5,599 Accrued interest 3,556 11,078 Deferred revenue 5,824 5,558 Liabilities held for sale — 6,556 Other current liabilities 30,507 32,180 Total Current Liabilities 146,205 174,011 Deferred Income Tax Liability 277,253 280,907 Non-Current Debt (note 7) 792,530 874,810 Other Non-Current Liabilities 43,519 42,854 Total Liabilities 1,259,507 1,372,582 Commitments and Contingencies (note 9) Equity Preferred stock, $ 1.00 par value, 100,000 shares authorized, none issued and outstanding — — Common stock, $ 0.16 par value, 315,000,000 shares authorized, 217,298,626 and 217,044,098 shares issued and outstandin

View Full Filing

View this 10-Q filing on SEC EDGAR